Stensland Michael D, Jacobson Jennie G, Nyhuis Allen
Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, United States.
J Affect Disord. 2007 Aug;101(1-3):187-93. doi: 10.1016/j.jad.2006.11.019. Epub 2007 Jan 23.
Bipolar disorder is a chronic and costly condition. This analysis examines health care costs associated with bipolar disorder in 2004 and contrasts them with those for depression, a better understood mental illness.
Health care costs associated with bipolar disorder and non-bipolar depression were determined using private payer administrative claims. Individuals having 2 claims with a primary ICD-9-CM code for bipolar disorder or depression were categorized as bipolar disorder or non-bipolar depression patients, respectively. Comparisons between patient groups were adjusted for demographic differences and comorbid diagnoses.
On average, bipolar patients (n=6072) used significantly more psychiatric resources per person than depression patients (n=60,643), and had more mean psychiatric hospital days, psychiatric and medical emergency room visits, and psychiatric office visits (p<.001 for all). Bipolar patients were slightly less likely to be treated with antidepressants, but substantially more likely to be treated with antipsychotics, anticonvulsants, lithium, and benzodiazepines (p<.001 for all). Mean direct per-patient costs were $10,402 for bipolar patients and $7494 for depression patients (p<.001), with the primary differences observed for psychiatric medication ($1641 vs. $507) and psychiatric hospitalization ($1187 vs. $241).
Patients were categorized based on diagnostic codes in administrative claims data, which may not always be accurate. Results may not generalize beyond private payer populations in the US.
Bipolar disorder is associated with significantly greater per-patient total annual health care costs than non-bipolar depression, as well as significantly greater psychiatric costs. Bipolar disorder, a chronic condition often suboptimally treated, may represent a good target for disease-management programs.
双相情感障碍是一种慢性且花费高昂的疾病。本分析考察了2004年与双相情感障碍相关的医疗保健费用,并将其与抑郁症(一种人们了解较多的精神疾病)的费用进行对比。
使用私人医保机构的管理索赔数据来确定与双相情感障碍和非双相情感障碍性抑郁症相关的医疗保健费用。有两条索赔记录且主要ICD-9-CM编码为双相情感障碍或抑郁症的个体分别被归类为双相情感障碍患者或非双相情感障碍性抑郁症患者。对患者组之间的比较进行了人口统计学差异和共病诊断的调整。
平均而言,双相情感障碍患者(n = 6072)每人使用的精神科资源显著多于抑郁症患者(n = 60643),且平均精神科住院天数、精神科和医疗急诊室就诊次数以及精神科门诊就诊次数更多(所有p值均<0.001)。双相情感障碍患者接受抗抑郁药治疗的可能性略低,但接受抗精神病药、抗惊厥药、锂盐和苯二氮䓬类药物治疗的可能性显著更高(所有p值均<0.001)。双相情感障碍患者的人均直接费用为10402美元,抑郁症患者为7494美元(p<0.001),主要差异体现在精神科药物(1641美元对507美元)和精神科住院治疗(1187美元对241美元)方面。
患者是根据管理索赔数据中的诊断编码进行分类的,这可能并不总是准确的。结果可能不适用于美国私人医保人群以外的情况。
与非双相情感障碍性抑郁症相比,双相情感障碍患者的人均年度总医疗保健费用显著更高,精神科费用也显著更高。双相情感障碍是一种治疗往往不够理想的慢性病,可能是疾病管理项目的一个良好目标。